Search

Displaying results 1771 - 1780 of 7687 in total
  1. Drug

    Methohexital

    go.drugbank.com/drugs/DB00474
    Approved

    An intravenous anesthetic with a short duration of action that may be used for induction of anesthesia.

    Synonyms: α-DL-1-methyl-5-allyl-5-(1'-methylpentyn-2-yl)barbituric acid
  2. Drug

    Motexafin lutetium

    go.drugbank.com/drugs/DB05296
    Investigational

    Motexafin lutetium (MLu) is a second-generation photosensitizer for photodynamic therapy (PDT) of cancer. It belongs to the family of drugs called metallotexaphyrins. Also called lutetium texaphyrin. Motexafin lutetium is a pentadentate ...

  3. Drug

    Tiopronin

    go.drugbank.com/drugs/DB06823
    Approved

    It is similar to d-penicillamine in use and efficacy, but offers the advantage of far less adverse effects. … Tiopronin may also be used to bind metal nanoparticles in Wilson's disease, which is an overload of copper in the body.

    International brands: Kai Na
  4. Drug

    Insulin lispro

    go.drugbank.com/drugs/DB00046
    ApprovedInvestigational

    Due to its duration of action of around 5 hours, Humalog is considered "bolus insulin" as it provides high levels of insulin in a short period of time to mimic the release of endogenous insulin from the … Without an adequate supply of insulin to promote absorption of glucose from the bloodstream, blood sugar levels can climb to dangerously high levels and can result in symptoms such as fatigue, headache

    Mixtures: HUMALOG MIX 25 SUSPENSION FOR INJECTION 100 iu/ml, HUMALOG MIX 25 SUSPENSION FOR INJECTION 100 iu/mlProducts: HUMALOG 100 U/ML, HUMALOG INJECTION 100 iu/ml
  5. Drug

    Idursulfase

    go.drugbank.com/drugs/DB01271
    ApprovedInvestigational

    Idursulfase is an enzyme that hydrolyzes the 2-sulfate esters of terminal iduronate sulfate residues from the glycosaminoglycans dermatan sulfate and heparan sulfate in the lysosomes of various cell types

  6. Drug

    Pembrolizumab

    go.drugbank.com/drugs/DB09037
    ApprovedInvestigational

    [L38934,L43257] In September 2025, the US FDA approved a formulation of pembrolizumab that includes [berahyaluronidase alfa] (Keytruda QLEX) to allow for subcutaneous administration.[L54026] … [F136] It was developed by Merck & Co and first approved for the treatment of metastatic malignant melanoma by the FDA on September 4, 2014,[L2954] becoming the first approved therapy against PD-1.

  7. Drug

    Moroctocog alfa

    go.drugbank.com/drugs/DB13999
    Approved

    extended half-life compared with conventional factor VIII due to conjugation to the dimeric Fc domain of human immunoglobulin G1, a long-lived plasma protein [A31551]. … Also known as Anti-Hemophilic Factor (AHF), endogenous Factor VIII is essential to the clotting process in the body due to its involvement in the clotting cascade where it is responsible for acting as

    Products: Xyntha 250 IU Powder and Solvent for Solution for Injection, Xyntha 1000 IU Powder and Solvent for Solution for Injection
  8. Drug

    Eprosartan

    go.drugbank.com/drugs/DB00876
    ApprovedInvestigational

    Eprosartan is an angiotensin II receptor antagonist used to treat hypertension. It performs 2 actions on the renin angiotensin system.

  9. Drug

    Ravulizumab

    go.drugbank.com/drugs/DB11580
    ApprovedInvestigational

    [A244465] Ravulizumab was first approved by the FDA on December 21, 2018, for the treatment of paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome in children and adults.

  10. Drug

    Atosiban

    go.drugbank.com/drugs/DB09059
    ApprovedInvestigational

    Atosiban is an inhibitor of the hormones oxytocin and vasopressin. It is used intravenously to halt premature labor.